Ironwood updates interim CFO compensation
Ironwood Pharmaceuticals amends a prior report to detail compensation for Ronald Silver in his new role as interim chief financial officer and principal financial officer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K/A
Rhea-AI Filing Summary
Ironwood Pharmaceuticals amends a prior report to detail compensation for Ronald Silver in his new role as interim chief financial officer and principal financial officer. Effective with this role, the board’s Compensation and HR Committee approved a monthly interim assignment fee of $12,250 for Mr. Silver.
On May 19, 2026, Mr. Silver also received a grant of 25,000 restricted stock units under the 2019 Amended and Restated Equity Incentive Plan. These RSUs will vest over two years, with 50% vesting on each approximate anniversary of the grant date, aligning the interim CFO’s pay more closely with the company’s share performance.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Interim CFO monthly fee: $12,250 per month
RSUs granted: 25,000 RSUs
RSU vesting schedule: 50% each year over 2 years
+2 more
5 metrics
Interim CFO monthly fee
$12,250 per month
Monthly interim assignment fee for Ronald Silver as interim CFO
RSUs granted
25,000 RSUs
Restricted stock units granted May 19, 2026 for interim CFO role
RSU vesting schedule
50% each year over 2 years
Vests on each approximate anniversary of May 19, 2026 grant date
Form type
Form 8-K/A
Amendment No. 1 providing compensation details for interim CFO
Grant date
May 19, 2026
Date Compensation and HR Committee approved fee and RSU grant
Key Terms
restricted stock units, 2019 Amended and Restated Equity Incentive Plan, interim chief financial officer, principal financial officer, +1 more
5 terms
restricted stock units financial
"Mr. Silver received a grant of 25,000 restricted stock units (“RSUs”) representing the right to receive shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2019 Amended and Restated Equity Incentive Plan financial
"awards granted under the Company’s 2019 Amended and Restated Equity Incentive Plan"
interim chief financial officer financial
"in connection with Mr. Silver’s new role as interim chief financial officer and principal financial officer"
An interim chief financial officer is a temporary leader responsible for managing a company's financial activities, such as budgeting, financial planning, and reporting, during a transitional period. Think of it as filling in for a key manager until a permanent replacement is found. For investors, this role is important because it ensures financial stability and clear guidance during times of change or uncertainty.
principal financial officer financial
"Mr. Silver’s new role as the Company’s interim chief financial officer and principal financial officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
Compensation and HR Committee financial
"compensation arrangements approved by the Compensation and HR Committee (the “Committee”) of the board of directors"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change did Ironwood Pharmaceuticals (IRWD) disclose in this 8-K/A?
Ironwood Pharmaceuticals disclosed updated compensation terms for Ronald Silver in his role as interim chief financial officer and principal financial officer, including a monthly interim assignment fee and an equity grant of restricted stock units tied to the company’s Class A common stock.
How much is Ronald Silver’s interim CFO monthly assignment fee at IRWD?
Ronald Silver will receive a monthly interim assignment fee of $12,250 for serving as interim chief financial officer and principal financial officer. This fee continues until a permanent chief financial officer is appointed or the interim assignment ends for another reason approved by the company.
What equity award did Ironwood Pharmaceuticals grant to interim CFO Ronald Silver?
Ironwood Pharmaceuticals granted Ronald Silver 25,000 restricted stock units (RSUs) representing the right to receive shares of Class A common stock. These RSUs were issued under the company’s 2019 Amended and Restated Equity Incentive Plan in connection with his interim CFO responsibilities.
How do Ronald Silver’s RSUs at IRWD vest over time?
Ronald Silver’s 25,000 RSUs vest over two years, with 50% of the units vesting on each approximate anniversary of the May 19, 2026 grant date. This schedule spreads the equity compensation across two annual vesting dates linked to his service period.
When did Ironwood’s board committee approve Ronald Silver’s interim CFO compensation?
The Compensation and HR Committee approved Ronald Silver’s interim CFO compensation on May 19, 2026. On that date, it authorized the $12,250 monthly interim assignment fee and granted 25,000 restricted stock units associated with his role as interim chief financial officer and principal financial officer.
How long will Ronald Silver receive the interim CFO assignment fee at IRWD?
Ronald Silver’s $12,250 monthly interim CFO assignment fee continues until the earlier of Ironwood Pharmaceuticals appointing a chief financial officer or the termination of the interim assignment for any other reason, as determined within the company’s governance structure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
